Abstract
GDC-0853 is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) that is highly selective and noncovalent, leading to reversible binding. In double-blind, randomized, and placebo-controlled phase I healthy volunteer studies, GDC-0853 was well tolerated, with no dose-limiting adverse events (AEs) or serious AEs. The maximum tolerated dose was not reached during dose escalation (≤600 mg, single ascending dose (SAD) study; ≤250 mg twice daily (b.i.d.) and ≤500 mg once daily, 14-day multiple ascending dose (MAD) study). Plasma concentrations peaked 1-3 hours after oral administration and declined thereafter, with a steady-state half-life ranging from 4.2-9.9 hours. Independent assays demonstrated dose-dependent BTK target engagement. Based on pharmacokinetic/pharmacodynamic (PK/PD) simulations, a once-daily dosing regimen (e.g., 100 mg, q.d.) is expected to maintain a high level of BTK inhibition over the dosing interval. Taken together, the safety and PK/PD data support GDC-0853 evaluation in rheumatoid arthritis, lupus, and other autoimmune or inflammatory indications.
References
Aug 1, 1995·Seminars in Immunology·D J Rawlings, O N Witte
Feb 9, 1996·Science·D J RawlingsJ P Kinet
May 1, 1996·Immunity·H ParkO N Witte
Oct 23, 1997·Proceedings of the National Academy of Sciences of the United States of America·M I WahlD J Rawlings
Jul 31, 1999·European Journal of Immunology·L M MorroghC Kinnon
Aug 10, 2000·Immunological Reviews·A B Satterthwaite, O N Witte
May 15, 2004·Immunity·Flavius Martin, Andrew C Chan
Nov 6, 2004·Arthritis and Rheumatism·Jennifer H AnolikIñaki Sanz
Nov 9, 2006·Blood·Klára SochorováRadek Spísek
Mar 14, 2007·Arthritis Research & Therapy·Claudia Mauri, Michael R Ehrenstein
Apr 21, 2010·Internal Medicine Journal·K MontagG Littlejohn
Jan 18, 2011·International Immunopharmacology·Donald MacGlashanJohn T Schroeder
Apr 28, 2011·The Journal of Pharmacology and Experimental Therapeutics·Lichuan LiuHarvey Wong
Dec 24, 2011·Arthritis Research & Therapy·Tamara K Nowling, Gary S Gilkeson
Aug 22, 2012·Nature Reviews. Rheumatology·William P Arend, Gary S Firestein
May 16, 2013·Scandinavian Journal of Immunology·L VargasC I E Smith
Sep 27, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrew L RankinJohn Douhan
Jan 28, 2014·PloS One·Joan Ní GabhannCaroline A Jefferies
Aug 27, 2015·Clinical and Translational Allergy·Marta Ferrer
Nov 26, 2015·European Journal of Immunology·Fanlei HuZhanguo Li
Nov 28, 2015·Annals of the Rheumatic Diseases·Akilan KrishnamurthyAnca I Catrina
May 20, 2016·Scientific Reports·Samantha A ChalmersChaim Putterman
Oct 22, 2016·ACS Chemical Biology·Adam R JohnsonWendy B Young
Nov 9, 2016·The Journal of Pharmacology and Experimental Therapeutics·Rebecca I EricksonDinah L Misner
Apr 14, 2017·JCI Insight·Arna KatewaKarin Reif
Feb 20, 2018·Journal of Medicinal Chemistry·James J CrawfordWendy B Young
Mar 22, 2018·Oncotarget·John C ByrdIan W Flinn
Citations
Jul 18, 2018·Current Opinion in Allergy and Clinical Immunology·Emek Kocatürk, Torsten Zuberbier
Aug 4, 2019·Clinical Pharmacology and Therapeutics·Nicholas S JonesLeslie W Chinn
May 10, 2020·CPT: Pharmacometrics & Systems Pharmacology·Yuan ChenLeslie W Chinn
Jun 15, 2020·Clinical Pharmacology and Therapeutics·Matthew R DurkPo-Chang Chiang
Apr 10, 2020·Arthritis & Rheumatology·Stanley CohenMark C Genovese
Jun 7, 2019·Allergy, Asthma & Immunology Research·Taek Ki Min, Sarbjit S Saini
Aug 3, 2019·The Journal of Pharmacology and Experimental Therapeutics·Nicholas Steven JonesLeslie Chinn
Nov 15, 2019·HemaSphere·Deyan Y YosifovDaniel Mertens
Dec 7, 2019·Blood Advances·Luise GoldmannWolfgang Siess
Sep 8, 2020·Platelets·Wolfgang SiessReinhard Lorenz
Jan 8, 2020·Pharmaceutical Research·Phyllis ChanAngelica Quartino
Sep 29, 2020·British Journal of Clinical Pharmacology·Tobias LitzenburgerJianan Hui
Feb 9, 2021·PLoS Neglected Tropical Diseases·Conall SauveyRuben Abagyan
Jan 23, 2021·Journal of Medicinal Chemistry·Zhouling XieChenzhong Liao
Mar 8, 2021·Journal of Hematology & Oncology·Danling GuYi Miao
Apr 4, 2021·Cancers·Philipp von Hundelshausen, Wolfgang Siess
Apr 22, 2021·Current Treatment Options in Allergy·Melanie C Dispenza
Jun 19, 2021·Clinical & Translational Immunology·Eris BameMichael Mingueneau
May 28, 2021·Arthritis & Rheumatology·David IsenbergKatie Tuckwell
Oct 9, 2021·Clinical Pharmacology and Therapeutics·Amy MengCara H Nelson
Nov 5, 2021·Journal of Medicinal Chemistry·Brian T HopkinsJoseph Lyssikatos